Search company, investor...

RxKinetix

rxkinetix.com

Founded Year

1996

Stage

Acquired | Acquired

Total Raised

$11.86M

Valuation

$0000 

About RxKinetix

RxKinetix is a product-focused specialty pharmaceutical company engaged in the research and development of novel pharmaceutical formulations. The company's lead product is RK-0202, an oral rinse for the prevention and treatment of oral mucositis, a painful and debilitating side-effect of cancer therapy. RxKinetix also has an emerging anti-viral formulation for the prevention and treatment of herpes simplex outbreaks, as well as programs involving vaccine, therapeutic antibody, and growth factor formulations.

Headquarters Location

3122 Sterling Circle Suite 200

Boulder, Colorado, 80301,

United States

303-926-1900

Missing: RxKinetix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: RxKinetix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing RxKinetix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RxKinetix is included in 1 Expert Collection, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Latest RxKinetix News

Awarded Grant by the National Institute Of Allergy and Infectious Diseases

Jul 11, 2017

Grant to Fund Early Research of an Anthrax Vaccine Using Company's Proprietary Technology Sep 24, 2002, 01:00 ET from RxKinetix, Inc. LOUISVILLE, Colo., Sept. 24 /PRNewswire/ -- RxKinetix, Inc. today announced that it has been awarded a $224,500 grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund early stage development of a novel adjuvant/delivery system for anthrax vaccine. The program will use the company's proprietary ProJuvant(TM) technology, in collaboration with research conducted at the Medical College of Ohio, in an effort to create an improved vaccine against the infectious bacterium, Bacillus anthracis. This project builds on the successful use of ProJuvant in proof-of-concept studies with tetanus that have demonstrated superior vaccine potency with reduced frequency of administration using the approaches that will be taken with anthrax. ProJuvant is a polymer-based matrix that incorporates an immune response enhancer. The resulting adjuvant, which is liquid at ambient or cool temperatures, becomes a pliable gel at body temperature for improved immune system exposure to the antigen. It can be dosed through systemic injections or non-invasive, intranasal administration. These formulations also may allow many conventional vaccines to be administered in single-doses without the common immunization/boost schedule. Preparation and production of the novel vaccine formulation will be carried out at RxKinetix's Colorado location, while testing of the vaccine will be performed under contract by an independent laboratory. "This grant from the NIAID further validates the innovative work we're doing with the delivery of vaccine candidates," said RxKinetix President and Chief Executive Officer, John E. Lucas. "The project is an extension of our ongoing vaccine research. It will help us to seek a tool against anthrax and to develop other company projects in which the goal is to improve immune responses." This Phase I grant is expected to fund a year of research. Should the program prove successful, the company will apply for a larger Phase II grant. RxKinetix, Inc. is a product-focused specialty pharmaceutical company engaged in the research and development of novel pharmaceutical formulations. The company's lead product is RK-0202, an oral rinse for the prevention and treatment of oral mucositis, a painful and debilitating side-effect of cancer therapy. RxKinetix also has an emerging anti-viral formulation for the prevention and treatment of herpes simplex outbreaks, as well as programs involving vaccine, therapeutic antibody, and growth factor formulations. More information regarding RxKinetix is available at www.rxkinetix.com . MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X31250383 SOURCE RxKinetix, Inc. LOUISVILLE, Colo., Sept. 24 /PRNewswire/ -- RxKinetix, Inc. today announced that it has been awarded a $224,500 grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund early stage development of a novel adjuvant/delivery system for anthrax vaccine. The program will use the company's proprietary ProJuvant(TM) technology, in collaboration with research conducted at the Medical College of Ohio, in an effort to create an improved vaccine against the infectious bacterium, Bacillus anthracis. This project builds on the successful use of ProJuvant in proof-of-concept studies with tetanus that have demonstrated superior vaccine potency with reduced frequency of administration using the approaches that will be taken with anthrax. ProJuvant is a polymer-based matrix that incorporates an immune response enhancer. The resulting adjuvant, which is liquid at ambient or cool temperatures, becomes a pliable gel at body temperature for improved immune system exposure to the antigen. It can be dosed through systemic injections or non-invasive, intranasal administration. These formulations also may allow many conventional vaccines to be administered in single-doses without the common immunization/boost schedule. Preparation and production of the novel vaccine formulation will be carried out at RxKinetix's Colorado location, while testing of the vaccine will be performed under contract by an independent laboratory. "This grant from the NIAID further validates the innovative work we're doing with the delivery of vaccine candidates," said RxKinetix President and Chief Executive Officer, John E. Lucas. "The project is an extension of our ongoing vaccine research. It will help us to seek a tool against anthrax and to develop other company projects in which the goal is to improve immune responses." This Phase I grant is expected to fund a year of research. Should the program prove successful, the company will apply for a larger Phase II grant. RxKinetix, Inc. is a product-focused specialty pharmaceutical company engaged in the research and development of novel pharmaceutical formulations. The company's lead product is RK-0202, an oral rinse for the prevention and treatment of oral mucositis, a painful and debilitating side-effect of cancer therapy. RxKinetix also has an emerging anti-viral formulation for the prevention and treatment of herpes simplex outbreaks, as well as programs involving vaccine, therapeutic antibody, and growth factor formulations. More information regarding RxKinetix is available at www.rxkinetix.com . MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X31250383 SOURCE RxKinetix, Inc.

RxKinetix Frequently Asked Questions (FAQ)

  • When was RxKinetix founded?

    RxKinetix was founded in 1996.

  • Where is RxKinetix's headquarters?

    RxKinetix's headquarters is located at 3122 Sterling Circle, Boulder.

  • What is RxKinetix's latest funding round?

    RxKinetix's latest funding round is Acquired.

  • How much did RxKinetix raise?

    RxKinetix raised a total of $11.86M.

  • Who are the investors of RxKinetix?

    Investors of RxKinetix include Endo International, National Institute of Allergy and Infectious Diseases, MedVenture Associates, Aweida Venture Partners, Elan and 3 more.

  • Who are RxKinetix's competitors?

    Competitors of RxKinetix include Kala Pharmaceuticals, Peckforton Pharmaceuticals, Somaxon Pharmaceuticals, Nycomed, Quark Pharmaceuticals and 12 more.

Compare RxKinetix to Competitors

N
Novast Pharmaceuticals

Novast is a generic and specialty pharmaceutical company, operated in both China and the United States. Novast is dedicated to upholding the highest quality and drug delivery technology in product development and commercial manufacturing. The company integrates science and technology with quality in all disciplines to develop and supply cost-effective and affordable products with global strategic alliances for the worldwide regulated markets.

C
Century Pharmaceuticals

Century Pharmaceuticals is a generic drug manufacturer based in India.

F
Fada Pharma

Fada Pharma is Argentina's leading manufacturer of generic pharmaceuticals for the institutional market

K
Kydes Pharmaceuticals

Kydes Pharmaceuticals, LLC is a start-up pharmaceutical company with a vision to design scientifically sound and cost-effective pharmaceutical products based on the knowledge and technologies

M
Marksans Pharma

Marksans Pharma (formerly Glenmark Laboratories) is one of the pharmaceuticals company in India, with a focused approach on creating a world class, global, pharmaceutical company. Its manufacturing plant is an in Asia and is approved by UK-MCHRA and Australian-TGA authorities. Marksans' focus is to become a preferred supplier for formulation outsourcing by first world countries, develop a marketing presence in the EU and, through a combination of licensing and partnering, become a integrated pharmaceutical company. It has just completed the reverse takeover of TASC Pharmaceuticals, a publicly quoted API company, to form a corporation valued at $120 million.

H
Heritage Pharmaceuticals

Heritage Pharmaceuticals Inc. is a rapidly growingngeneric pharmaceutical company engaged in thenacquisition, licensing, development, marketing,nsale and distribution of generic pharmaceuticalnproducts for the global prescriptionndrug markets.n nHeritage has established itself as a competitor in thengeneric pharmaceutical industry by initially targetingnniche products with revenues that are generally toonsmall to command the resources and attention ofnmajor market participants. Heritage launched its U.S. label in 2006 and has rapidly built a portfolio of highnquality multi-source generic pharmaceutical productsnacross multiple therapeutic categories, including: ncardiovascular, pain management, anti-infectives andnmetabolic disease.n nThe company's business model aims to utilize strategicnoutsourcing to U.S.F.D.A. qualified manufacturingnand development organizations in both NorthnAmerica and Asia. The Company will continuento introduce its new generic products during 2008nfollowing its tradition quality, value andnservice in generics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.